In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections

被引:13
作者
Ganière, JP
Médaille, C
Etoré, F
机构
[1] Ecole Natl Vet, Unite Pathol Infect, F-44307 Nantes 03, France
[2] Vebiotel, F-94110 Arcueil, France
[3] Schering Plough Corp, F-92320 Levallois Perret, France
关键词
dog; pyoderma; otitis; Staphylococcus intermedius; orbifloxacin; MIC; time-kill kinetic;
D O I
10.1016/j.rvsc.2004.02.002
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
The objective of the study was to evaluate the in vitro activity of orbifloxacin against Staphylococcus intermedius strains isolated in France from canine skin and ear infections. The minimum inhibitory concentrations (MICs) of orbifloxacin against 240 field S. intermedius isolates (69 skin and 171 ear isolates) ranged from 0.016 to 8 mg l(-1), with MIC50 and MIC90 equal to 0.5 and 1 mg l(-1), respectively. Only one strain, a pyoderma isolate was resistant (MIC = 8 mg l(-1)). Orbifloxacin was tested at different concentrations for killing rate against five isolates obtained from pyoderma cases and against a reference strain (Stapylococcus aureus ATCC(R) 29213). Orbifloxacin expressed a concentration-dependent bactericidal activity against the S. aureus reference strain, but a time-dependent bactericidal activity against S. intermedius. Orbifloxacin induced bactericidal effect against the S. intermedius strains tested with concentrations equal to or two times MIC. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:67 / 71
页数:5
相关论文
共 24 条
[1]   ACCUMULATION AND KILLING KINETICS OF 15 QUINOLONES FOR ESCHERICHIA-COLI, STAPHYLOCOCCUS-AUREUS AND PSEUDOMONAS-AERUGINOSA [J].
ASUQUO, AE ;
PIDDOCK, LJV .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (06) :865-880
[2]   Fluoroquinolones in animal health [J].
Brown, SA .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1996, 19 (01) :1-14
[3]  
Cester CC, 1996, REV MED VET-TOULOUSE, V147, P703
[4]  
COELHOBAPTISTA B, 2003, J VET PHARM THER S1, V26, P155
[5]   Microbial flora and antimicrobial susceptibility patterns from dogs with otitis media [J].
Colombini, S ;
Merchant, SR ;
Hosgood, G .
VETERINARY DERMATOLOGY, 2000, 11 (04) :235-239
[6]  
Dowling PM, 1996, CAN VET J, V37, P695
[7]   PHARMACODYNAMICS AND PHARMACOKINETICS OF ANTIBIOTICS WITH SPECIAL REFERENCE TO THE FLUOROQUINOLONES [J].
DUDLEY, MN .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 :S45-S50
[8]   Antimicrobial activity of enrofloxacin against Staphylococcus intermedius strains isolated from canine pyodermas [J].
Ganière, JP ;
Médaille, C ;
Limet, A ;
Ruvoen, N ;
André-Fontaine, G .
VETERINARY DERMATOLOGY, 2001, 12 (03) :171-175
[9]   Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration [J].
Heinen, E .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2002, 25 (01) :1-5
[10]   THE IMPORTANCE OF PHARMACOKINETIC-PHARMACODYNAMIC SURROGATE MARKERS TO OUTCOME - FOCUS ON ANTIBACTERIAL AGENTS [J].
HYATT, JM ;
MCKINNON, PS ;
ZIMMER, GS ;
SCHENTAG, JJ .
CLINICAL PHARMACOKINETICS, 1995, 28 (02) :143-160